- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03048136
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)
April 13, 2018 updated by: Bristol-Myers Squibb
A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RIO Negro
-
Viedma, RIO Negro, Argentina, 8500
- Local Institution
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H1M 1B1
- Local Institution
-
-
-
-
-
Dresden, Germany, 01307
- Local Institution
-
Gauting, Germany, 82131
- Local Institution
-
Gerlingen, Germany, 70839
- Local Institution
-
Grosshansdorf, Germany, 22927
- Local Institution
-
-
-
-
-
Lima, Peru
- Local Institution
-
Lima, Peru, 27
- Local Institution
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Local Institution
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Local Institution
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Local Institution
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Local Institution
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Local Institution
-
Langhorne, Pennsylvania, United States, 19047
- Local Institution
-
Sayre, Pennsylvania, United States, 18840
- Local Institution
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Local Institution
-
-
Utah
-
Saint George, Utah, United States, 84770
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- 1) Stage IV or recurrent non-Small cell lung cancer
- 2) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- 3) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization
Exclusion Criteria:
- 1) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
- 2) Active, known or suspected autoimmune disease or HIV infection
- 3) Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
- 4) Untreated Central Nervous System metastases
Other protocol defined inclusion/exclusion criteria could apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Flat-Dose
Nivolumab flat dose + Ipilimumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
EXPERIMENTAL: Weight-Based Dose
Nivolumab weight-based dose + Ipilimumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events
Time Frame: Approximately 3 months
|
Approximately 3 months
|
|
Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events
Time Frame: Approximately 3 months
|
Approximately 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Overall survival (OS) as defined as the time from first dosing to the date of death
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
March 9, 2018
Primary Completion (ANTICIPATED)
September 29, 2019
Study Completion (ANTICIPATED)
September 29, 2019
Study Registration Dates
First Submitted
February 8, 2017
First Submitted That Met QC Criteria
February 8, 2017
First Posted (ESTIMATE)
February 9, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 17, 2018
Last Update Submitted That Met QC Criteria
April 13, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Ipilimumab
Other Study ID Numbers
- CA209-955
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.